Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02058940 · ClinicalTrials.gov registry record · Phase 4
Intravenous Exenatide in Patients With Acute Brain Injury
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT02058940 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 8 participants.
The verdict
NCT02058940, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.
Interventions
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02058940
The ClinicalTrials.gov registry entry for NCT02058940 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exenatide is the first listed.
NCT02058940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02058940 about?
NCT02058940 is a clinical study titled "Intravenous Exenatide in Patients With Acute Brain Injury". The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.
What is the current status of trial NCT02058940?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2015-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02058940?
The interventions under investigation include: Exenatide (DRUG).
Who is sponsoring clinical trial NCT02058940?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.